Key Investor Signals
Received pre-seed investment from Zinc Ventures
Mana Medical secured pre-seed funding from Zinc Ventures after being selected for its eighth venture-building cohort, adding external investor validation at an early stage.
Running an 8-week beta study with NRAS recruitment support
The National Rheumatoid Arthritis Society is supporting recruitment into Mana Medical’s eight-week beta study, giving the company direct access to adults with rheumatoid or inflammatory arthritis.
Built patient and clinician products for arthritis monitoring
Mana Medical has built both a patient-facing self-management product and a clinician dashboard for monitoring enrolled patients and prioritising those who may need attention.
Other Positive Signals
- Selected for DigitalHealth.London Launchpad’s seventh cohort, a UK Government-funded programme.
- Designed around Medicare-recognised Remote Therapeutic Monitoring CPT codes 98975–98981.
- Onboarding a small number of US rheumatology practices into a no-cost clinician product pilot.
Team
Jamie Baker
Co-Founder & Chief Executive Officer
- Senior Venture Lead at Accenture Song's Venture Studio for 2.5 years, focused on building and launching new ventures.
- Previously Strategy Lead at Bow&Arrow, creating new digital products, services and ventures for clients including Google, BMW MINI, Boots and American Express.
- Earlier Investment Associate at Angels Den Funding, giving him direct experience evaluating and supporting early-stage companies.
Dr Emma Dyson
Co-Founder & Chief Medical Officer
- Nearly four years of NHS clinical experience across acute medicine, emergency medicine and other hospital specialties.
- Recipient of three clinical excellence awards and the South Thames Foundation School E-Portfolio Award in 2022.
- Healthtech and innovation fellowship completed with Distinction, covering user validation, market sizing and medical regulation.
Product
Mana Medical combines a patient app with a clinician dashboard. Patients connect an existing wearable, including Apple Watch or Garmin, and complete a short daily symptom check-in. Clinicians receive a daily view of enrolled patients, scored and sorted by who may need attention.
Daily activity and pacing guidance
Mana combines wearable data with daily symptom check-ins to provide personalised activity guidance, helping patients judge how much exertion may be sustainable and avoid overexertion.
Patient Stability Index and auto-triage
The clinician dashboard calculates a daily Patient Stability Index and ranks enrolled patients by who may need attention, helping practices prioritise higher-risk cases for review.
Reimbursement-aligned documentation
Mana tracks qualifying monitoring days and prepares documentation for US Remote Therapeutic Monitoring claims, which practices can review before submitting for reimbursement.
Market Overview
Inflammatory arthritis affects a large patient population and can change substantially between visits. Versus Arthritis records 450,000 UK adults with rheumatoid arthritis and 190,000 with psoriatic arthritis. In a longitudinal early rheumatoid arthritis cohort, 45% of patients experienced at least one disease-activity flare during follow-up.
In the United States, Medicare reimburses certain forms of remote musculoskeletal monitoring through Remote Therapeutic Monitoring codes. At the same time, the rheumatology workforce is projected to face a shortage of more than 4,000 providers by 2030, increasing pressure on specialist capacity and creating demand for more efficient monitoring between visits.
Versus Arthritis records 450,000 UK adults with a diagnosis of rheumatoid arthritis, plus a further 190,000 with psoriatic arthritis.
In an early RA cohort, 45% of patients experienced at least one disease-activity flare during follow-up.
A US workforce study projects a shortage of more than 4,000 rheumatology providers by 2030.
MarketsandMarkets forecasts the US remote patient monitoring market to reach $29.13B by 2030.
Comparable Outcomes
Hinge Health
Hinge Health built software-guided musculoskeletal care for acute injuries, chronic pain and post-surgical recovery, with patients exercising at home alongside clinical support. Hinge Health went public on the NYSE in May 2025 at $32 per share, implying a valuation of about $2.6B and raising roughly $437M in the offering.
Preventice Solutions
Preventice Solutions developed wearable cardiac monitors and remote services that detected irregular heart rhythms outside hospitals. Boston Scientific acquired the company in March 2021 for up to $1.225 billion.
Interested in More Startups Like Mana Medical?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.